Zobrazeno 1 - 10
of 14
pro vyhledávání: '"G S Emelyanova"'
Autor:
G S Emelyanova, A E Kuzminov, N F Orel, A S Odintsova, A A Markovich, A A Kuznetsova, V A Gorbunova
Publikováno v:
Современная онкология, Vol 18, Iss 1, Pp 80-83 (2016)
Somatostatin analogs plays a key role in the treatment of disseminated well-differentiated functioning and nonfunctioning neuroendocrine tumors (NET). Its ingibit hormonal activity of NET by binding to somatostatin receptors, have antiproliferative e
Externí odkaz:
https://doaj.org/article/096f4df874c740de8cb54cfedc777cfe
Publikováno v:
Современная онкология, Vol 17, Iss 3, Pp 92-95 (2015)
Everolimus is the targeted drug approved for the treatment of neuroendocrine tumors (NET). Efficacy of everolimus in combination with octreotide-depo has been shown in Radiant-2 randomized trial in patients with well-differentiated NET in different l
Externí odkaz:
https://doaj.org/article/c9d46ea2b99742c4ba94b5121db4af31
Autor:
A. A. Markovich, A. A. Kuznetsova, V. A. Gorbunova, N. F. Orel, A. S. Odintsova, G. S. Emelyanova, A. E. Kuzminov
Publikováno v:
Медицинский совет, Vol 0, Iss 10, Pp 115-119 (2019)
The treatment efficacy and toxicity profile was evaluated in 33 patients with highly differentiated neuroendocrine tumors NEO (G1, G2), who received sunitinib therapy in various dose regimens. Stable disease was achieved in 24 patients (72.7%), parti
Externí odkaz:
https://doaj.org/article/29b703d41c8746dbadeff556b5ccdea9
Autor:
E. V. Evdokimova, E. V. Artamonova, V. V. Delectorskaya, G. Yu. Chemeris, G. S. Emelyanova, S. G. Bagrova, A. A. Markovich
Publikováno v:
Medical alphabet. :20-24
Considering the fact that the group of neuroendocrine carcinomas (NECs) grade 3 is heterogenous, in the year of 2017 a new subgroup of welldifferentiated neuroendocrine tumors grade 3 (NETs G3) was described. NETs G3 are tumors with more favorable pr
Autor:
A. D. Ryzhkov, A. A. Markovich, M. E. Bilik, S. M. Kaspshik, G. S. Emelyanova, E. V. Artamonova
Publikováno v:
Medical alphabet. :18-22
he disease incidence of neuroendocrine tumors (NET) is increasing every year. Neuroendocrine tumors Grade 1 and 2 have a more favorable prognosis than Grade 3. When we are talking about NET with non-detected initial focus, the 10-year survival rate i
Autor:
S. G. Bagrova, A. A. Kolomeytseva, N. S. Besova, А. A. Markovich, V. A. Gorbunova, E. V. Artamonova, N. V. Lyubimova, G. S. Emelyanova, Е. I. Kovalenko
Publikováno v:
Medical alphabet. :38-41
Advanced well differentiated neuroendocrine tumors (NET) have poor sensitivity to chemotherapy. Approaches to the second and subsequent lines of treatment have not been developed to date Aranosa is a derivative of nitrosourea. it is close to streptoz
Autor:
E. V. Artamonova, M. E. Bilik, S. M. Kaspshik, A. D. Ryzhkov, M. B. Dolgushin, G. S. Emelyanova, A. A. Markovich
Publikováno v:
Medical alphabet. :42-45
This article describes a new affordable diagnostic method of neuroendocrine tumors, shows the basic information on it’s conduction and interpretation of the results. Scintigraphy of neuroendocrine tumors with 99m Tc-Tectro-tyd is a new alternative
Autor:
S. G. Bagrova, N. S. Besova, E. I. Kovalenko, E. V. Artamonova, A. A. Markovich, G. S. Emelyanova, N. V. Lyubimova, V. A. Gorbunova
Publikováno v:
Medical alphabet. :19-24
Background. The diagnostics of neuroendocrine tumors (NET) is complex due to many factors such as the heterogeneity of the tumors themselves, different localization of the tumor process, and the presence of severe hormonal syndromes. A special place
Autor:
L Ya Rozhinskaya, Iya Voronkova, M. B. Dolgushin, D. V. Komov, G. S. Emelyanova, E. A. Kobyakova, Ekaterina Pigarova, S. V. Shiryaev, L. S. Kruglova, M. E. Bilik, Yu. A. Krupinova, Vera Gorbunova
Publikováno v:
Opuholi Golovy i Šei, Vol 6, Iss 4, Pp 67-72 (2017)
Parathyroid carcinoma (PC) is a rare neoplasm with a prevalence of only 0.005 % of all malignancies, and less than 1 % among patients with primary hyperparathyroidism. The diagnosis can be challenging due to the rarity of the disease, similarity of c
Autor:
G S Emelyanova, N. N. Kozlov, A A Markovich, V. V Delektorskaya, N F Orel, S. A. Polozkova, A S Odintsova, A E Kuzminov, Vera Gorbunova
Publikováno v:
Russian Journal of Biotherapy. 16:38-46